What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experience
Authors:
- 1 October 2015
- journal article
- research article
- Published by Elsevier in Bulletin du Cancer
- Vol. 102 (10) , 814-822
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialThe Lancet Oncology, 2014
- Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) studyAnnals of Oncology, 2012
- Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group StudyJournal of Clinical Oncology, 2007
- Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to ChemotherapyJournal of Clinical Oncology, 2004
- Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma PatientsJournal of Clinical Oncology, 2004
- Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcomaEuropean Journal of Cancer, 2001
- High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma groupBritish Journal of Cancer, 1998
- Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomasAnnals of Oncology, 1997
- High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.Journal of Clinical Oncology, 1997
- Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicityCancer Treatment Reviews, 1993